AF atrialfibrillation
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Reported monosodiumglutamate triggered atrial fibrillation Age is between 18 and 80 years AF is symptomatic and paroxysmal AF was documented on ECG, Holter or pacemaker electrogram at least once in the 6 months preceding presentation In sinus rhythm at the moment of study inclusion Legally competent and willing and able to sign informed consent Willing and able to adhere to the follow up visit protocol
Exclusion criteria
Exclusion criteria: Myocardial infarction (defined as CKMB> twice upper limit of normal) within the preceding 2 months NYHA class IV/IV heart failure symptoms, or class II-III with a recent decompensation requiring hospitalization (unless related to or aggravated by AF) Cerebrovascular accident (defined as any sudden neurological deficit lasting longer than 24 hours, with or without pathological changes on the CT cerebrum) with the preceding 6 months Known and documented carotid stenosis>80% Pregnancy or of childbearing potential without adequate contraception Requirement of antiarrhythmic medication for ventricular arrhythmias Left ventricular ejection fraction40 ml/m2 or left atrial diameter>52 mm History of previous radiation therapy on the thorax Circumstances that prevent follow-up (no permanent home or address, transient, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study will be AF, confirmed by Holter or 12-lead ECG. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are two or more symptoms of the MSG symptom complex. | — |
Countries
Netherlands
Outcome results
None listed